About TBMC

The rapid progress, production, and global distribution of mRNA vaccines have played a pivotal role in combating the effects of COVID-19 worldwide. In the early stages of vaccine rollout, the supply of mRNA vaccines was primarily directed to the countries engaged in their development and production, leading to a temporary shortage of vaccines in Taiwan.
Consequently, a country‘s ability to quickly manufacture advanced biological pharmaceuticals through Contract Development and Manufacturing Organization (CDMO) services is closely linked to protecting the health and welfare of its citizens.
Taiwan Bio-Manufacturing Corporation (TBMC), established in May 2023, specializes in cutting-edge biotechnology, including viral vectors, cell therapies, and protein technologies. Born from collaborations with the Department Center for Biotechnology (DCB) and Industrial Technology Research Institute (ITRI), TBMC is rapidly advancing in biopharmaceutical manufacturing.
With state-of-the-art technologies like Raman spectroscopy and automated cell culturing system, TBMC aims to become Asia's first Pharma 4.0 CDMO, delivering high-quality biologics medicines.
Previous
Next
TBMC典範複製_英文版__new
TBMC典範複製_英文版__new2
Previous
Next

Milestone

Expected to be operational in Q3 of 2024

Process Development Lab Taipei
Bioinnovation Park

1,820 m2

Expected to be operational by the end of 2026

GMP Plant
Hsinchu Biomedical Science Park

15,000 m2

Expected to be operational in Q3 of 2024

Process Development Lab Taipei Bioinnovation Park

1,820 m2

Expected to be operational by the end of 2026

GMP Plant Hsinchu Biomedical Science Park

15,000 m2

Team